![\"\"](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\")
<\/p>\n<\/p>\n
In spite of several approved therapies, the currently the Myelodysplastic Syndrome Therapeutics market faces high unmet medical needs. In order to provide effective therapeutics options, some of the key companies in the domain such as <\/span>Astex Pharmaceuticals, Onconova Therapeutics, Celgene, Aprea Therapeutics, Celyad, <\/strong>and others are actively involved in developing therapies. Apart from the therapeutics front, the progress in the research and the development is also likely to strengthen the treatment approaches and quality of care against MDS in the coming years.\u00a0<\/span><\/p>\n DelveInsight\u2019s <\/span>Myelodysplastic Syndrome Pipeline Insights<\/strong><\/a> report provides a comprehensive outlook of the pipeline therapies that are in different clinical and pre-clinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Myelodysplastic Syndrome domain.<\/span><\/p>\n The <\/span>Myelodysplastic Syndrome Pipeline Analysis<\/strong><\/a> report offers a 360\u00b0 view of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for Myelodysplastic Syndrome emerging therapies.<\/span><\/p>\n The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.\u00a0<\/span><\/p>\n Myelodysplastic syndromes are a group of disorders that occur when the blood-forming cells in the bone marrow become abnormal as a result of which the body is unable to produce healthy blood cells. People affected with Myelodysplastic Syndrome have a high symptom burden and faces the risk of death from complications of cytopenias and AML.<\/span><\/p>\n The treatment\u2019s goal of MDS is to relieve symptoms, slow the progression of the disease, avoid complications and other side effects. Current treatment approaches include systemic therapy with (intensive chemotherapy and Immune therapy), stem cell transplantation, and supportive Therapies. However, the remission or progression of the disease is high, which possess serious challenges in long term.\u00a0<\/span><\/p>\n Some of the key highlights from the Myelodysplastic Syndrome Pipeline<\/a> report:<\/strong><\/p>\n Request for Sample @ Myelodysplastic Syndrome Pipeline Insights and Outlook<\/strong><\/a><\/p>\n Myelodysplastic Syndrome Pipeline Analysis<\/a>: Drug Profile\u00a0<\/strong><\/p>\n The report provides an in-depth analysis of the drug in different stages of development including detailed clinical profiles, launch date, and recent product development activities. Some of the key drugs covered in the report include:<\/span><\/p>\n KER-050 is an engineered ligand trap consisting of a modified ligand-binding domain of the TGF-\u03b2 receptor. It is being developed by Keros Therapeutics for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.<\/span><\/p>\n Guadecitabine (SGI-110) is a second-generation DNA methylation inhibitor. It is currently being evaluated in Phase III clinical trial in subjects with MDS or chronic myelomonocytic leukemia who have failed or relapsed after adequate prior treatment with azacitidine, decitabine, or both.<\/span><\/p>\n Rigosertib is a small molecule, which acts as a Ras mimetic, and binds to the Ras-binding domain (RBD) found in many Ras effector proteins, including the Raf and PI3K kinase; however, it does not interact at the ATP binding site but acts via allosteric inhibition.<\/span><\/p>\n APR-246 is the lead molecule being developed by Aprea Therapeutics. The drug has been shown to reactivate mutant p53 and thereby induce programmed cell death in human cancer cells.<\/span><\/p>\n![\"Myelodysplastic-Syndromes-pipeline\"](\"http:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Myelodysplastic-Syndromes-pipeline.jpg?1620188133591\")
<\/span><\/p>\n\n
\n
\n
\n
\n